Studiencode: GER1701_P16-537_HOPE
| Institution: | AbbVie GmbH & Co. KG | Auftraggeber: | AbbVie GmbH & Co. KG |
| Titel der NIS: | Impact of adalimumab (Humira®) therapy on ocular inflammation,selected health care resource utilization and patient reported outcomesin patients with active non-infectious intermediate, posterior and panuveitis in routine clinical practice – HOPE | ||
| Ziel der NIS: | This study aimed to evaluate real life effectiveness of originatoradalimumab (Humira®) in patients with active non-infectiousintermediate, posterior and panuveitis (NIIPPU) despite high-dosecorticosteroid therapy; including effect on ocular inflammation, health-related quality of life, health care resource utilization, work ability andmedication burden. In addition, its purpose was to describe thecharacteristics of NIIPPU patients treated with adalimumab (Humira®)in the real-life setting. |
||
| Ort der Durchführung: | multinational | NIS angefordert: | nein |
| Patientenanzahl insgesamt: | 106 | Anzahl Ärzte insgesamt: | 24 |
| Patientenanzahl in Deutschland: | 22 | Ärzte in Deutschland: | 3 |
| Anzeige am: | 16.11.2017 | Geplanter Beginn: | 20.06.2017 | Geplantes Ende: | 24.02.2020 |
| Angezeigtes Ende der NIS am: 13.08.2020 | |||||
| Arzneimittelbezeichnung | INN | Zulassungs-Nr. | ATC-Code | Substanzklasse |
|---|---|---|---|---|
| HUMIRA | Adalimumab | EU/1/03/256/012../19 | L04AB04 | Tumor necrosis factor alpha (TNF-α) inhibitors |
